Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.

[1]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[2]  F. Werf.  A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .

[3]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[4]  E. Braunwald,et al.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.

[5]  W. V. Mieghem.  A comparison of continuous infusion of alteplase with double bolus administration for acute myocardial infarction: the continuous infusion versus double double bolus administration of alteplase , 1997 .

[6]  F. Verheugt.  A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. , 1997, The New England journal of medicine.

[7]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[8]  B. Keyt,et al.  New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. , 1995, Circulation.

[9]  L. Barrios,et al.  A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. , 1995, Circulation.

[10]  D. Botstein,et al.  A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[12]  B. Keyt,et al.  A Slow Clearing, Fibrin-Specific, PAI-1 Resistant Variant of t-PA (T103N, KHRR 296-299 AAAA) , 1993, Thrombosis and Haemostasis.

[13]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.